Press release
November twenty five, 2022
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, announced today Composition of the Nominating Committee 2023 Annual Meeting.
In accordance with the instructions and charter of the Nominating Committee adopted by the General Assembly, the Nominating Committee will consist of three members, the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of September last year. You and shall. On 30 September 2022, Jørgen Drejer and Dan Peters were his two major shareholders who wanted to appoint representatives to the nominating committee. Each such shareholder has appointed a representative, as set out below, who, together with the Chairman of the Board, constitutes Saniona AB’s nominating committee.
Members of the Nominating Committee are:
- John Haurum, Professional Director of Life Sciences Company and former CEO of F-star Biotechnology Limited, Cambridge, UK, appointed by Jørgen Drejer
- Søren Skjærbæk, partner at Ursus Law Firm, Vejle, Denmark, appointed by Dan Peters
- Jørgen Drejer, Chairman of the Saniona AB Board of Directors
The Nominating Committee shall prepare and submit to the 2023 Annual Meeting proposals on:
- Election of President at Annual Meeting
- Election of Chairman and other Board members.
- Remuneration of the Chairman and each other member of the Board and, where applicable, remuneration for the work of the Committees.
- Auditor Selection and Auditor Compensation.When
- Principles for the appointment of the nominating committee.
Saniona AB’s nominating committee instructions and articles of incorporation are available on the company’s website, www.saniona.com, in the Corporate Governance section.
Saniona AB’s Annual General Meeting will be held on Thursday 25 May 2023 in Malmö. The nominating committee’s proposals will be posted in the annual general meeting notice and on the company’s website.
Shareholders wishing to submit their proposals to the Nomination Committee may do so by sending an email to clo@saniona.com marked “Recommendation for Nomination Committee” or by regular mail to the following address: I can.
Recommendation to Nomination Committee
Saniona AB
Smederand 26B
DK-2600 Gross trap
Denmark
Proposals must be submitted by the deadline prior to the Annual General Meeting, but no later than February 25, 2023, to ensure that the nominating committee can consider the proposals.
Contact us for more information
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
Information has been submitted for publication through the agency of the contact person identified above. 1Five:30 CET on twenty five November 2022.
About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of drugs that modulate ion channels. The company’s most advanced product candidate, Tesomet™, is progressing into intermediate-stage clinical trials for a rare eating disorder. Saniona is advancing his two product candidates, SAN711 and SAN903, through his expertise in ion channels. SAN711 has successfully completed a Phase 1 clinical trial for the treatment of neuropathic pain. SAN903 is ready for Phase 1 clinical trials for the treatment of inflammatory and fibrotic diseases. The company has research and development partnerships with Boehringer Ingelheim GmbH, Products Medix, SA de SV and Cephagenix ApS. Based in Copenhagen, Denmark, Saniona is listed on the NASDAQ Stockholm Small Cap (OMX: SANION). For more information, please visit www.saniona.com.
-
20221125 Nominating Committee
